Ignite Creation Date:
2025-12-24 @ 5:42 PM
Ignite Modification Date:
2026-02-22 @ 4:13 PM
Study NCT ID:
NCT05609968
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2022-11-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Carcinoma, Non-Small-Cell Lung | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Programmed Cell Death-1 (PD1, PD-1) | View |
| None | Programmed Death-Ligand 1 (PDL1, PD-L1) | View |
| None | Programmed Cell Death-2 (PD2, PD-2) | View |
| None | Programmed Death-Ligand 2 (PDL2, PD-L2) | View |
| None | Trophoblast Cell Surface Antigen-2 (TROP-2) | View |
| None | Antibody-Drug Conjugate (ADC) | View |